Newer treatment options in hyperkalemia management implemented in clinical practice

Panagiotis I. Georgianos, MD, PhD

Assistant Professor of Nephrology, 2nd Department of Nephrology, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Disclosures: Honoraria: **AstraZeneca, Boehringer Ingelheim**

HK is diagnosed based on serum K^+



HK, hyperkalemia

1. American Heart Association. *Circulation* 2005;112(Suppl.):121–125; 2. Einhorn LM, et al. *Arch Int Med* 2009;169:1156–1162.

Regulation of K^+ homeostasis



Clinical presentation of HK[2,3]

- ✓ Often asymptomatic
- ✓ In severe HK (K^+ >6.5 mEq/L), patients may present with muscle weakness, paralysis and sudden death
- ✓ Cardiac conduction abnormalities ranging from ECG changes to life-threatening arrhythmias may also occur in severe HK

Figure adapted from: Osorio FV, Linas SL[1]ECF, extracellular fluid; ECG, electrocardiogram; GI, gastrointestinal; HK, hyperkalemia; ICF, intracellular fluid

1. Osorio FV, Linas SL. Disorders of potassium metabolism. In: Schrier RW (ed.). *Atlas of Diseases of the Kidney, Vol. 1*; Oxford: Wiley-Blackwell; 1999; 2. Rastergar A, Soleimani M. *Postgrad Med J* 2001;77:759–764; 3. Pfortmüller CA et al. *Eur J Intern Med* 2013;24:e59–e60

Patient subgroups with a high incidence of HK



HiK is defined as K^+ >5.0 mEq/L[6]

CHF, chronic heart failure; CKD, chronic kidney disease; HF, heart failure; HiK, hyperkalaemia; MRA, mineralocorticoid receptor antagonist

1. Kovesdy CP. *Nat Rev Nephrol* 2014;10:653–662; 2. Vardeny O, et al. *Circ Heart Fail* 2014;7:573–579; 3. Nilsson E, et al. *ERA-EDTA*, Madrid, 2017. Poster presentation SP313; 4. Chomicki J, et al. Presented at ASH Annual Scientific Meeting & Exposition; 16th–20th May 2014; New York, NY, USA; P-10; 5. Khosla N, et al. *Am J Nephrol* 2009;30:418–424; 6. Yancy CW, et al. Circulation. 2017;136:e137–e161.

Conditions associated with HK often co-exist

Up to ~50% of patients with HF also have CKD



Diabetes is present in ~40% of patients hospitalized for acute HF



CKD, chronic kidney disease; HF, heart failure; HK, hyperkalemia
Aguilar D. *Circ Heart Fail* 2016;9:e003316

Recurrent HK episodes are common in CKD patients, with successively shorter time between the episodes



Population-based cohort study linking individual data from mandatory hospital, prescription, and laboratory databases in northern Denmark (population 1.8 million) during 2000–2012 (N=157,766)
CKD, chronic kidney disease; HK, hyperkalemia
Adapted from: Thomsen RW, et al. *Nephrol Dial Transplant* 2018;33:1610–1620

Rates of adverse clinical outcomes increase with severity of hyperkalemia



CKD, chronic kidney disease
Horne L, et al. Presented at 54th European Renal Association – European Dialysis and Transplant Association Congress; June 3rd–6th, 2017; Madrid, Spain; poster MP380 (retrospective analysis)

Recent studies confirm high serum K^+ levels are associated with increased risk of mortality and MACE in CKD – U shape association

- Retrospective observational study of 191,964 CKD patients from the CPRD – UK (stage 3a–5nonD) between 2006-2015
- Mean follow-up time of 4.96y, mean eGFR: 50.96 mL/min/1.73m2, **48.06%** received RAASi therapy, mean K^+ 4.47 mmol/L





CKD, chronic kidney disease; CPRD, Clinical Practice Research Datalink; HES, hospital episode statistics; IRR, incident risk ratio; MACE, major adverse cardiovascular events

Qin L, McEwan P, Evans M, Bergenheim K, Horne L, Grandy S; MO067. The Relationship Between Serum K^+ and Incidence Rates of Major Adverse Cardiovascular Events and Mortality in UK Patients With CKD. *Nephrol Dial Transplant*. 2017;32(Suppl 3):iii73–iii74, by permission of the European Renal Association–European Dialysis and Transplant Association.

RAASi therapy is recommended for the management of patients with CKD

NDD-CKD patients without diabetes mellitus

- KDIGO recommends that an ARB or ACEi be used in non-diabetic adults with NDD-CKD and urine albumin excretion >300 mg per 24 hours (or equivalent) in whom treatment with BP-lowering drugs is indicated (*1B*)

NDD-CKD patients with diabetes mellitus

- KDIGO recommends that an ARB or ACEi be used in adults with diabetes and NDD-CKD with urine albumin excretion >300 mg per 24 hours (or equivalent) (*1B*)

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CKD, chronic kidney disease; KDIGO, Kidney Disease Improving Global Outcomes; NDD-CKD, nondialysis-dependent chronic kidney disease; RAASi, renin–angiotensin–aldosterone system inhibitor

Kidney Disease Improving Global Outcomes CKD Work Group. *Kidney Int Suppl* 2012;2:337–414

RAASi therapy is recommended by clinical guidelines for the management of HF

ESC guidelines 2016[1]

Class	Level of evidence	Recommendation to reduce the risk of HF hospitalization and death in patients with HFrEF
I	ACEi: A	An ACEi[a] is recommended, in addition to a β blocker, for symptomatic patients
	MRA: A	An MRA is recommended for patients, who remain symptomatic despite treatment with an ACEi[a] and a β blocker
	ARB: B	An ARB is recommended in symptomatic patients unable to tolerate an ACEi (patients should also receive a β blocker and an MRA)
	ARNi: B	Sacubitril/valsartan is recommended as a replacement for an ACEi in ambulatory patients who remain symptomatic despite optimal treatment with an ACEi, a β blocker and an MRA[b]

ACC/AHA/HFSA guidelines – updated 2017[2]

Class	Level of evidence	Recommendation to reduce morbidity and mortality in patients with HFrEF
I	ACEi: A	The use of ACEi therapies is beneficial for patients with prior or current symptoms of chronic HFrEF
	ARB: A	The use of ARBs is recommended in patients with prior or current symptoms of chronic HFrEF who are intolerant to ACEi therapies because of cough or angioedema
	ARNi: B–R	In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACEi or ARB, replacement by an ARNi is recommended
Inhibition of RAAS with **ACEi**, **ARB**, or **ARNi** therapies in conjunction with evidence-based β blockers, and **MRAs** in selected patients, is recommended for patients with chronic HFrEF		

[a]Or ARB if ACEi is not toleratedor contraindicated; [b]Patient should have elevated natriuretic peptides (plasma BNP ≥150 pg/mL or plasma NT-proBNP ≥600 pg/mL, or if HF hospitalization within the last 12 months, plasma BNP ≥100 pg/mL or plasma NT-proBNP ≥400 pg/mL) and able to tolerate enalapril 10 mg BID

ACC, American College of Cardiology; ACEi, angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BID, twice daily; BNP, B-type natriuretic peptide; ESC, European Society of Cardiology; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFSA, Heart Failure Society of America; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RAAS(i), renin–angiotensin–aldosterone system (inhibitor)

1. Ponikowski P, et al. *Eur J Heart Fail* 2016;18:891–975; 2. Yancy CW, et al. *Circulation* 2017;136:e1372–e161

Over a 5-year period, 30% of patients on RAASi therapy experienced HK in a retrospective study of US healthcare records

Retrospective analysis of a US database of electronic health records (N>200,000) of patients with various comorbidities and at least two serum K^+ readings



[a]Mild: 5.1–5.4 mEq/L; [b]Moderate-to-severe: ≥5.5 mEq/L
HK, hyperkalemia; RAASi, renin–angiotensin–aldosterone system inhibitor
Epstein M, et al. *Am J Manag Care* 2015;21:S212–S220

The majority of patients not at target RAASi doses, regardless of patient subtype

Distribution of RAASi dose levels by comorbidity group[1]



HK among patients on ≥1 RAAS inhibitor prescription in a retrospective US study over a 5-year period; data include any services provided in hospitals as well as office and outpatient setting
[a]Comorbidity group does not exclude CKD stage 3 to 4; [b]Comorbidity group does not exclude HF; [c]Comorbidity group does not exclude CKD stage 3–4 or HF;
[d]DM was not excluded from these comorbidity groups
CKD, chronic kidney disease; DM, diabetes mellitus; HF, heart failure; RAASi, renin–angiotensin–aldosterone system inhibitor
Adapted from: Epstein M, et al. *Am J Manag Care* 2015;21:S212–S220

Patients with HF and CKD receiving less than 50% of ESC guideline-recommended RAASi dose had an increased risk of MACE

Data from the UK CPRD and linked HES identified patients on RAASi with new onset of HF (N=21,334) between January 2006 and December 2015



A limitation of this study was the absence of LVEF data, which would have given a more accurate indication of patient specific guideline dose.
CI, confidence interval; CKD, chronic kidney disease; CPRD, Clinical Practice Research Datalink; ESC, European Society of Cardiology; HES, Hospital Episodes Statistics; HF, heart failure; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; OR, odds ratio; RAASi, renin–angiotensin–aldosterone system inhibitor
Qin L, et al. Presented at European Society of Cardiology Congress 2018; August 25th–29th, 2018; Munich, Germany; poster 86856

ACE/ARB Discontinuation Associated with MACE/ Mortality in CKD G4

Cohort

3,909 patients from Geisinger Health System on ACE/ARB whose eGFR decreased below 30 ml/min/1.73 m^2 **(2004-2018)**

Mean age 74 years

62% women

Methods

People who discontinued therapy

1:1 propensity matching **1,205 in each group**

People who continued therapy







Conclusions Continuation of ACE/ARB therapy may be protective for mortality and major adverse cardiovascular events in advanced CKD without precipitating higher risk of ESKD (*In press, JAMA-IM*)

Traditional HK treatment options are associated with limitations

Low-K^+ diet[1]

- Difficult to adhere to
- Limiting K^+-rich foods can cause constipation
- Contradicts DASH diet; may worsen chronic hypertension

Diuretics[1]

- Efficacy depends on residual renal function (until diuresis is present)
- Increased risk of gout and diabetes depending on choice of diuretic
- May produce volume contraction, decreased distal nephron flow, worsening of kidney function, and reduced K^+ excretion depending on choice of diuretic

Discontinuation or dose reduction of RAASi therapy[1]

- Stopping or suboptimal utilization of renal/ cardioprotective RAASi therapy

Traditional potassium binders (SPS)[2–4]

- No long-term efficacy has been evaluated
- Gastric irritation, anorexia, nausea, vomiting, constipation, and occasionally diarrhea may occur
- Hard, gritty texture and unpleasant taste may reduce palatability

DASH, Dietary Approaches to Stop Hypertension; HK, hyperkalemia; RAASi, renin–angiotensin–aldosterone system inhibitor; SPS, sodium polystyrene sulfonate

1. Dunn J, et al. *Am J Manag Care* 2015;21:S307–S315; 2. Chaitman M, et al. *P T* 2016;41:43–50; 3. Sanofi-Aventis US LLC. Kayexalate US Prescribing Information 2018; 4. Zann V, et al. *Drug Des Devel Ther* 2017;11:2663–2673

Available potassium binders

- **SPS**: approved 1958
- Nonspecific sodium cation-exchange resin; may also bind calcium and magnesium



Newer binders in 21st century

- **Patiromer**: approved 2015/EU 2017
- Nonspecific cation-binding in exchange for calcium
- **SZC**: approved 2018/EU 2019
- Highly selective; preferentially captures K^+ ions

- [a]SPS was FDA-approved prior to the Kefauver–Harris Drug Amendments in 1962, which required drug manufacturers' to prove effectiveness of their product[3]

1. Chaitman M, et al. *P T* 2016;41:43–50; 2. Sanofi. Resonium A EU Summary of Product Characteristics 2019; 3. Sterns RH, et al. *J Am Soc Nephrol* 2010;21:733–735; 4. Garimella PS, Jaber BL. *Am J Kidney Dis* 2016;67:545–547; 5. Vifor Fresenius Medical Care Renal Pharma France. Veltassa (Patiromer) EU Summary of Product Characteristics 2018; 6. AstraZeneca AB. LOKELMA▼ EU Summary of Product Characteristics 2020

Sodium zirconium cyclosilicate (SZC): Crystal Structure



Average Binding-Site Width: 3 Å

- Inorganic crystalline zirconium silicate compound
- Not a polymer
- Insoluble, highly stable, and does not expand in water
- Not systemically absorbed
- High affinity for K^+
- Exchanges Na^+ and H^+ for K^+

SZC = sodium zirconium cyclosilicate.

Stavros F, et al. *PLoS One*. 2014;9:e114686 . Characterization of structure and function of ZS-9, a K^+ selective ion trap. *PLoS One*. 2014;9:e114686.

SZC Binds K^+ Throughout the GI Tract*



- Based on in vitro data, SZC may begin working immediately in the small intestine to preferentially capture K^+
- K^+ is exchanged for sodium and hydrogen

*For illustrative purposes only.
SZC = sodium zirconium cyclosilicate.

Stavros F, et al. *PLoS One*. 2014;9:e114686.

ZS-004

Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients with Hyperkalemia: The HARMONIZE Randomized Clinical Trial[1]

ZS-004E

Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE[2]



Research

Original Investigation

Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia
The HARMONIZE Randomized Clinical Trial

Mikhail Kosiborod, MD; Henrik S. Rasmussen, MD, PhD; Philip Lavin, PhD; Wajeh Y. Qunibi, MD; Bruce Spinowitz, MD; David Packham, MD; Simon D. Roger, MD; Alex Yang, MD; Edgar Lerma, MD; Bhupinder Singh, MD

IMPORTANCE Hyperkalemia is a common electrolyte abnormality that may be difficult to manage because of a lack of effective therapies. Sodium zirconium cyclosilicate is a nonabsorbed cation exchanger that selectively binds potassium in the intestine.

OBJECTIVE To evaluate the efficacy and safety of zirconium cyclosilicate for 28 days in patients with hyperkalemia.

DESIGN, SETTING, AND PARTICIPANTS HARMONIZE was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating zirconium cyclosilicate in outpatients with hyperkalemia (serum potassium ≥5.1 mEq/L) recruited from 44 sites in the United States, Australia, and South Africa (March-August 2014).

INTERVENTIONS Patients (n = 258) received 10 g of zirconium cyclosilicate 3 times daily in the initial 48-hour open-label phase. Patients (n = 237) achieving normokalemia (3.5-5.0 mEq/L) were then randomized to receive zirconium cyclosilicate, 5 g (n = 45 patients), 10 g (n = 51), or 15 g (n = 56), or placebo (n = 85) daily for 28 days.

MAIN OUTCOMES AND MEASURES The primary end point was mean serum potassium level in each zirconium cyclosilicate group vs placebo during days 8-29 of the randomized phase.

RESULTS In the open-label phase, serum potassium levels declined from 5.6 mEq/L at baseline to 4.5 mEq/L at 48 hours. Median time to normalization was 2.2 hours, with 84% of patients (95% CI, 79%-88%) achieving normokalemia by 24 hours and 98% (95% CI, 96%-99%) by 48 hours. In the randomized phase, serum potassium was significantly lower during days 8-29 with all 3 zirconium cyclosilicate doses vs placebo (4.8 mEq/L [95% CI, 4.6-4.9], 4.5 mEq/L [95% CI, 4.4-4.6], and 4.4 mEq/L [95% CI, 4.3-4.5] for 5 g, 10 g, and 15 g; 5.1 mEq/L [95% CI, 5.0-5.2] for placebo; $P < .001$ for all comparisons). The proportion of patients with mean potassium <5.1 mEq/L during days 8-29 was significantly higher in all zirconium cyclosilicate groups vs placebo (36/45 [80%], 45/50 [90%], and 51/54 [94%] for the 5-g, 10-g, and 15-g groups, vs 38/82 [46%] with placebo; $P < .001$ for each dose vs placebo). Adverse events were comparable between zirconium cyclosilicate and placebo, although edema was more common in the 15-g group (edema incidence: 2/85 [2%], 1/45 [2%], 3/51 [6%], and 8/56 [14%] patients in the placebo, 5-g, 10-g, and 15-g groups). Hypokalemia developed in 5/51 (10%) and 6/56 patients (11%) in the 10-g and 15-g zirconium cyclosilicate groups, vs none in the 5-g or placebo groups.

CONCLUSIONS AND RELEVANCE Among outpatients with hyperkalemia, open-label sodium zirconium cyclosilicate reduced serum potassium to normal levels within 48 hours; compared with placebo, all 3 doses of zirconium cyclosilicate resulted in lower potassium levels and a higher proportion of patients with normal potassium levels for up to 28 days. Further studies are needed to evaluate the efficacy and safety of zirconium cyclosilicate beyond 4 weeks and to assess long-term clinical outcomes.

TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02088073

Editorial page 2217

Supplemental content at jama.com

Author Affiliations: Saint Luke's Mid America Heart Institute, Kansas City, Missouri (Kosiborod); University of Missouri-Kansas City (Kosiborod); ZS Pharma, Coppell, Texas (Rasmussen, Singh); Boston Biostatistics Research Foundation, Framingham, Massachusetts (Lavin); University of Texas Health Science Center at San Antonio (Qunibi); Weill Medical College of Cornell University, New York, New York (Spinowitz); Melbourne Renal Research Group and Department of Medicine, University of Melbourne, Melbourne, Australia (Packham); Renal Research, Gosford, Australia (Roger); Xelay Acumen, Belmont, California (Yang); University of Illinois at Chicago College of Medicine, Chicago (Lerma); Advocate Christ Medical Center, Oak Lawn, Illinois (Lerma).

Corresponding Author: Mikhail Kosiborod, MD, Saint Luke's Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111 (mkosiborod@saint-lukes.org).

JAMA. 2014;312(21):2223-2233. doi:10.1001/jama.2014.15688
Published online November 17, 2014. Corrected on May 21, 2015.



Nephrology

Patient-Oriented, Translational Research: Research Article

Am J Nephrol 2019;50:473–480
DOI: 10.1159/000504078

Received: July 30, 2019
Accepted: October 10, 2019
Published online: October 28, 2019

Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE

Simon D. Roger[a] Bruce S. Spinowitz[b] Edgar V. Lerma[c] Bhupinder Singh[d, e] David K. Packham[f] Ayman Al-Shurbaji[g] Mikhail Kosiborod[h, i]

[a]Renal Research, Gosford, NSW, Australia; [b]Division of Nephrology, Department of Medicine, NewYork-Presbyterian Queens, New York, NY, USA; [c]Section of Nephrology, Advocate Christ Medical Center, University of Illinois at Chicago, Oak Lawn, IL, USA; [d]ZS Pharma, Inc., Part of AstraZeneca, San Mateo, CA, USA; [e]School of Medicine, University of California, Irvine, CA, USA; [f]Melbourne Renal Research Group and Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; [g]AstraZeneca, Gothenburg, Sweden; [h]Department of Cardiology, Saint Luke's Mid America Heart Institute and Department of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA; [i]The George Institute for Global Health and University of New South Wales, Sydney, NSW, Australia

Keywords
Extension · HARMONIZE · Hyperkalemia · Sodium zirconium cyclosilicate

Abstract

Background: Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K^+) binder for treatment of hyperkalemia. An open-label extension (OLE) of the HARMONIZE study evaluated efficacy and safety of SZC for ≤11 months. ***Methods:*** Patients from HARMONIZE with point-of-care device i-STAT K^+ 3.5–6.2 mmol/L received once-daily SZC 5–10 g for ≤337 days. End points included achievement of mean serum K^+ ≤5.1 mmol/L (primary) or ≤5.5 mmol/L (secondary). ***Results:*** Of 123 patients who entered the extension (mean serum K^+ 4.8 mmol/L), 79 (64.2%) completed the study. The median daily dose of SZC was 10 g (range 2.5–15 g). The primary end point was achieved by 88.3% of patients, and 100% achieved the secondary end point. SZC was well tolerated with no new safety concerns. ***Conclusion:*** In the HARMONIZE OLE, most patients maintained mean serum K^+ within the normokalemic range for ≤11 months during ongoing SZC treatment.

Introduction

Hyperkalemia (serum potassium [K^+] >5.0 or >5.5 mmol/L) [1, 2] has an adverse prognosis, and severe hyperkalemia can be life threatening [3]. Oral K^+ binders, which lower serum K^+ by binding K^+ in the colon, reducing K^+ absorption and increasing K^+ fecal excretion [4], are potential therapeutic options for long-term hyperkalemia management. Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a K^+ binder approved for the treatment of hyperkalemia in the United States and Europe [5–7]. In clinical trials, including HARMONIZE [8], SZC reduced serum K^+ to within the normokalemic range within 48 h, which was maintained over 29 days in most patients

KARGER

E-Mail karger@karger.com
www.karger.com/ajn

Karger Open access

Simon D. Roger, MD
Renal Research
37 William Street
Gosford, NSW 2250 (Australia)
E-Mail sdroger@bigpond.net.au

1. Kosiborod M et al. *JAMA*. 2014;312:2223-2233; 2. Roger SD et al. *Am J Nephrol.* 2019;50:473-480.

ZS-004 (HARMONIZE) + ZS-004E (Extension)
Study Designs

ZS-004[1]

Phase III, multicenter, 2-phase prospective study in patients with serum K^+ ≥5.1 mmol/L at 44 nephrology, cardiology, general research sites in US, South Africa, and Australia

ZS-004E (EXTENSION)[2]

Extension phase of patients who completed ZS-004 at 30 sites in US, South Africa, and Australia



*Proceeded to maintenance phase if patient achieved normokalemia (i-STAT K^+ 3.5-5.0 mmol/L) by morning of study Day 3; †Two patients with i-STAT K^+ >5.5 mmol/L at the end of ZS-004 entered the correction phase of ZS-004E where they received SZC 10 g TID with meals and proceeded to the 11-month maintenance phase within 1 day once normokalemia (i-STAT K^+ 3.5-5.0 mmol/L) was achieved. The remaining patients with i-STAT K^+ 3.5-5.5 mmol/L at the end of ZS-004 immediately entered the 11-month maintenance phase to receive SZC 10 g QD.

1. Kosiborod M et al. Article and protocol. *JAMA*. 2014;312:2223-2233; 2. Roger SD et al. Article and supplementary material. *Am J Nephrol.* 2019;50:473-480.

ZS-004 (HARMONIZE) + ZS-004E (Extension)
Efficacy Endpoints

crystalize HARMONIZE & Extension

	ZS-004[1]	ZS-004E[2]
Primary	**Randomized Maintenance Phase:** • Comparison of mean serum K^+ levels between placebo and each SZC treatment group from Day 8 to Day 29	Proportion of patients with mean serum K^+ ≤5.1 mmol/L during 11-month maintenance phase (Day 8 through Day 337)
Key Secondary	**Open-label Correction Phase:** • Change from baseline in serum K^+ levels at all time intervals • Proportion of patients achieving normokalemia by 24 and 48 hours • Time to K^+ normalization **Randomized Maintenance Phase:** • Proportion of patients with mean K^+ level <5.1 mmol/L during Days 8 to 29	Proportion of patients with average serum K^+ ≤5.5 mmol/L during 11-month maintenance phase (Day 8 through Day 337)

Note: Normokalemia defined as serum K^+ 3.5–5.0 mmol/L.

1. Kosiborod M et al. *JAMA*. 2014;312:2223-2233; 2. Roger SD et al. *Am J Nephrol.* 2019;50:473-480.

ZS-004 (HARMONIZE)
Patient Demographics and Baseline Characteristics

	Correction Phase	Maintenance Phase			
Parameter	**SZC 10 g TID (n=258)**	**Placebo QD (n=85)**	**SZC 5 g QD (n=45)**	**SZC 10 g QD (n=51)**	**SZC 15 g QD (n=56)**
Age, years, mean (SD),	64.0 (12.7)	64.3 (12.1)	61.5 (16.9)	63.8 (10.0)	64.9 (12.9)
Sex, n (%)					
Male	149 (57.8)	44 (51.8)	27 (60.0)	27 (52.9)	40 (71.4)
Female	109 (42.2)	41 (48.2)	18 (40.0)	24 (47.1)	16 (28.6)
Race, n (%)					
White	215 (83.3)	73 (85.9)	36 (80.0)	44 (86.3)	46 (82.1)
Black/African American	37 (14.3)	10 (11.8)	8 (17.8)	5 (9.8)	9 (16.1)
Asian	5 (1.9)	3 (3.5)	0	1 (2.0)	1 (1.8)
Other	3 (1.2)	1 (1.2)	1 (2.2)	1 (2.0)	0
Weight, kg, mean (SD)	87.9 (22.9)	85.1 (18.6)	89.6 (23.9)	87.4 (25.6)	87.2 (18.6)
Comorbidities, n (%)					
Chronic kidney disease	169 (65.5)	50 (58.8)	29 (64.4)	36 (70.6)	37 (66.1)
Heart failure	94 (36.4)	26 (30.6)	18 (40.0)	18 (35.3)	25 (44.6)
Diabetes mellitus	170 (65.9)	54 (63.5)	26 (57.8)	38 (74.5)	39 (69.6)
RAASi medications, n (%)	180 (69.8)	61 (71.8)	33 (73.3)	36 (70.6)	33 (58.9)

RAASi = renin–angiotensin–aldosterone system inhibitors; SD = standard deviation; SZC = sodium zirconium cyclosilicate.

Kosiborod M et al. *JAMA*. 2014;312:2223-2233.

LOKELMA: Onset of action at 1 hour

- One dose of LOKELMA significantly reduced (–0.2 mEq/L) serum K^+ levels **at 1 hour** vs baseline (*P*<0.001)[1,2]
- **88% of patients achieved normokalemia** during the 48-hour correction phase[2]
- The median time to serum K+ normalisation was 2.2 hours (interquartile range 1.1 to 22.3)[1]

Mean serum K^+ level with LOKELMA 10 g three times daily for 48 hours (N=258)[1a]



Open-label phase
mean baseline serum K^+:
5.6 mEq/L

Comorbidities/treatment at baseline: CKD (60%), HF (11%), T2DM (66%),[3b] and RAASi use (70%)[1]

[a]In the open-label 48-h phase of the HARMONIZE trial; [b]Note: CKD, HF, and T2DM percentages have been updated based on revised definitions according to Medical Dictionary for Regulatory Activities[3]
CKD, chronic kidney disease; HF, heart failure; RAASi, renin–angiotensin–aldosterone system inhibitor; T2DM, Type 2 diabetes mellitus
1. Kosiborod M, et al. *JAMA* 2014;312:2223–2233; 2. AstraZeneca AB. LOKELMA EU Summary of Product Characteristics 2020; 3. AstraZeneca. Data on file 2018; REF-34756

ZS-004 (HARMONIZE)
Correction Phase: Mean Serum K^+ Levels in Predefined Subgroups

SZC consistently reduced serum K^+, regardless of comorbidities, use of RAASi therapy, or baseline K^+ level[1-3]



Note: Normokalemia defined as serum K^+ 3.5–5.0 mmol/L. Error bars indicated 95% CI.

*The definitions used to identify subjects with baseline comorbid conditions (across the ZS Pharma clinical development program) were based on custom lists of preferred terms. AstraZeneca has elected to use more recognized definitions that are based on the standardized Medical Dictionary for Regulatory Activities query (narrow) for each comorbid condition. For example in the original HF population (n=94), the mean change from baseline in K^+ was -1.173 mmol/L at 48 hours. Based on the AstraZeneca re-analysis, the percentage of patients with HF is 11% (28/251) with a mean change in K^+ of -1.196 mmol/L at 48 hours.[3]; †Baseline eGFR <60 mL/min/1.73 m^2.[1]

CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; HF = heart failure; RAASi = renin–angiotensin–aldosterone system inhibitor; SZC = sodium zirconium cyclosilicate.

1. Kosiborod M et al. *JAMA*. 2014;312:2223-2233; 2. LOKELMA Summary of Product Characteristics; 3. In House Data, AstraZeneca Pharmaceuticals LP. LOKELMA (sodium zirconium cyclosilicate) oral suspension. Subgroups based on comorbid conditions at baseline in ZS clinical studies. Doc ID-003819479. April 4, 2018.

ZS-004 (HARMONIZE) + ZS-004E (Extension)
Mean Serum K⁺ Levels Correction, Maintenance and Extension Phases





88% of patients receiving SZC maintained an average serum K⁺ of <5.1 mmol/L over 11 months

Mean decreases in serum K⁺ from HARMONIZE-CP BL were observed at every time point during the Extension-MP, ranging from –1.0 to –0.8 mmol/L (–17.8 to –14.4%; p ≤0.001 for all)

Note: Normokalemia defined as serum K⁺ 3.5–5.0 mmol/L. Error bars indicate 95% CI.

*p<0.001 vs. baseline; †p<0.001 vs. placebo during Days 8-29; ‡ITT population in Extension-MP consisted of patients who received ≥1 SZC dose with any post-Extension-CP BL safety data and post-Extension-MP serum K⁺ measurements. Off-drug values were recorded at 7±1 days following the last dose of SZC; §Mean SZC doses to maintain normokalemia were 10 g QD in 73.2%, >10 g QD in 13.0%, <10 g QD in 13.8% of patients.

BL = baseline; CP = correction phase; ITT = intent-to-treat; MP = maintenance phase; SZC = sodium zirconium cyclosilicate.

1. Kosiborod M et al. *JAMA*. 2014;312:2223-2233; 2. Roger SD et al. Article and supplementary material. *Am J Nephrol.* 2019;50:473-480.

ZS-004 (HARMONIZE)

Maintenance Phase: Patients With Mean Serum K^+ <5.1 mmol/L During Days 8–29



*p<0.001 vs. placebo.

SZC = sodium zirconium cyclosilicate.

Kosiborod M et al. *JAMA*. 2014;312:2223-2233.

ZS-004E (Extension)
Mean Serum K⁺ Levels in Extension Phases





88% of patients receiving SZC maintained an average serum K⁺ of <5.1 mmol/L over 11 months

Mean decreases in serum K⁺ from HARMONIZE-CP BL were observed at every time point during the Extension-MP, ranging from –1.0 to –0.8 mmol/L (–17.8 to –14.4%; p ≤0.001 for all)

Note: Normokalemia defined as serum K⁺ 3.5–5.0 mmol/L. Error bars indicate 95% CI.

*p<0.001 vs. baseline; †p<0.001 vs. placebo during Days 8-29; ‡ITT population in Extension-MP consisted of patients who received ≥1 SZC dose with any post-Extension-CP BL safety data and post-Extension-MP serum K⁺ measurements. Off-drug values were recorded at 7±1 days following the last dose of SZC; §Mean SZC doses to maintain normokalemia were 10 g QD in 73.2%, >10 g QD in 13.0%, <10 g QD in 13.8% of patients.

BL = baseline; CP = correction phase; ITT = intent-to-treat; MP = maintenance phase; SZC = sodium zirconium cyclosilicate.

1. Kosiborod M et al. *JAMA*. 2014;312:2223-2233; 2. Roger SD et al. Article and supplementary material. *Am J Nephrol.* 2019;50:473-480.

ZS-004E (Extension)
RAASi Dosing During the Study

Of the 83 (68%) patients who received RAASi at the start of the extension maintenance phase:

- **78% Maintained same** RAASi dose
- **8% Increased** RAASi dose
- **4% Added** another RAASi
- **4% Changed** RAASi dose*
- **2% Switched** RAASi therapy
- **4% Discontinued** RAASi therapy

Of the 38 RAASi-naïve patients at extension phase baseline:

- **11% Initiated** RAASi therapy

*Multiple dose increases and decreases.

RAASi = renin–angiotensin–aldosterone system inhibitor.

Roger SD et al. *Am J Nephrol.* 2019;50:473-480.

ZS-004 (HARMONIZE)
Adverse Events

Adverse Events Occurring in ≥5% of Patients, n (%)	Correction Phase	Maintenance Phase			
	SZC 10 g TID (n=258)	Placebo QD (n=85)	SZC 5 g QD (n=45)	SZC 10 g QD (n=51)	SZC 15 g QD (n=56)
Any event	20 (7.8)	27 (31.8)	24 (53.3)	15 (29.4)	25 (44.6)
Blood and lymphatic system disorders					
Anemia	0	0	0	0	3 (5.4)
Gastrointestinal disorders*					
Constipation	2 (0.8)	6 (7.1)	0	1 (2.0)	1 (1.8)
General disorders and administration-site conditions					
Edema†	0	2 (2.4)	1 (2.2)	3 (5.9)	8 (14.3)
Metabolism and nutrition disorders					
Hypokalemia (<3.5 mmol/L)‡	0	0	0	5 (9.8)	6 (10.7)
Hypokalemia (reported as AE)	0	0	0	0	1 (1.8)
Infections and infestations					
Nasopharyngitis	0	1 (1.2)	0	0	3 (5.4)
Upper respiratory tract infection	1 (0.4)	1 (1.2)	3 (6.7)	1 (2.0)	1 (1.8)

- **No clinically relevant changes in serum electrolytes (Na^+, Mg^{2+}, or Ca^{2+}), vital signs, blood pressure, heart rate, or body weight**
- **No dose-dependent increase in urinary sodium excretion**

*Gastrointestinal adverse events were reported in 14% (12/85) in placebo group, 7% (3/45) in SZC 5 g group, 2% (1/51) in SZC 10 g group, and 9% (5/56) in SZC 15 g group; †Included terms edema, generalized edema, or peripheral edema as treatment-emergent adverse event. Of the 14 patients who developed edema, 5 patients in the SZC 15 g group required change in therapy; ‡All cases of hypokalemia were mild (3.0–3.4 mmol/L) and resolved after dose reduction.

AE = adverse event; SZC = sodium zirconium cyclosilicate.

Kosiborod M et al. *JAMA*. 2014;312:2223-2233.

ZS-004E (Extension)
Adverse Events

Extension-MP Safety Population,* N=123	n (%)
Adverse Events Occurring in ≥5% of Patients	**82 (66.7)**
Constipation†	7 (5.7)
Hypertension‡	15 (12.2)
Peripheral edema	10 (8.1)
Urinary tract infection	11 (8.9)
AEs leading to discontinuation in ≥2 patients	**11 (8.9)**
Electrocardiogram QT interval prolonged§	2 (1.6)
SAEs leading to discontinuation	**6 (4.9)‖**
Serious Adverse Events in ≥2 Patients	**24 (19.5)**
Chronic obstructive pulmonary disease	2 (1.6)
Congestive cardiac failure	2 (1.6)
Pneumonia	2 (1.6)
Urinary tract infection	2 (1.6)

- **16 patients (13%) reported SMQ edema, of which 11 had significant risk factors for fluid overload–related events,** including history of heart failure, diastolic dysfunction, CKD, edema, lymphedema, or venous insufficiency¶
- **No clinically meaningful changes in weight or blood pressure were observed**
- 2 patients experienced hyperkalemia as an AE (1 was considered a serious AE and 1 lead to discontinuation), both patients had a serum K^+ of 7.0 mmol/L at discontinuation

Note: Interpretation of safety results are limited as study was open-label and lacked a placebo comparator arm.

*Extension-MP safety population included all patients who received ≥1 dose of SZC during the extension-MP and had any post–extension-correction phase baseline safety data; †Overall, 23 patients (18.7%) reported gastrointestinal disorders. Nausea, vomiting, diarrhea were each reported in 3.3% of patients; ‡As reported by site with no specific threshold. Hypertension was rated as mild (n=7; 46.7%) or moderate (n=8; 53.3%) in severity and only 1 case was considered related to SZC by the investigator. No patients discontinued study medication due to an AE of hypertension; §Non-serious; possibly related to SZC; ‖Including cardiac failure, acute myocardial infarction, hyperkalemia, chronic obstructive pulmonary disease, localized infection, and diabetic foot infection. No SAEs were considered related to SZC; ¶SMQ edema includes preferred terms from the Standardized MedDRA Queries for hemodynamic edema, effusions, and fluid overload; In the 16 patients, there were 17 SMQ edema events. None of the edema events led to discontinuation.

AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities; MP = maintenance phase; SAE = serious adverse event; SMQ = Standardized Medical Dictionary for Regulatory Activities query; SZC = sodium zirconium cyclosilicate.

Roger SD et al. Article and supplementary material. *Am J Nephrol.* 2019;50:473-480.

International Urology and Nephrology
https://doi.org/10.1007/s11255-022-03142-3

NEPHROLOGY - ORIGINAL PAPER

Prevalence, recurrence and seasonal variation of hyperkalemia among patients on hemodialysis

Dimitra Tsiagka[1] · Panagiotis I. Georgianos[1,2] · Maria I. Pikilidou[1] · Vasilios Valos[1] · Stefanos Roumeliotis[1] · Christos Syrganis[2] · Konstantinos Mavromatidis[2] · Simeon Metallidis[1] · Vassilios Liakopoulos[1] · Pantelis E. Zebekakis[1]





Fig. 1 Proportion of patients experiencing a hyperkalemic event (≥ 5.1, ≥ 5.5≥ 6.0 mmol/L) at baseline (June 2020) and at least once at any time point over the 1-year-long follow-up period

Rationale for DIALIZE

- Hyperkalemia is prevalent in patients with advanced CKD, especially when they reach ESRD.[1]
- Despite adequate HD, 30%-50% of patients have hyperkalemia.[2,3] Hyperkalemia is prevalent particularily after the LIDI.[4]
- Predialysis hyperkalemia is associated with increased all-cause mortality and CV mortality.[4]
- Arrhythmias/cardiac arrests account for 44% of deaths in patients on chronic dialysis.[5] In patients on HD, higher mortality rates are observed after the LIDI.[6-8]
- Hyperkalemia is independently associated with greater short-term risk of hospitalizations and ED visits, and with greater hospital costs.[9]
- Data on how to optimally manage hyperkalemia in dialysis patients has been limited to date.[10]

The DIALIZE study is the first randomized, placebo-controlled trial to evaluate the efficacy and safety of a potassium binder in the treatment of hyperkalemia in HD patients[11]

CKD = chronic kidney disease; CV = cardiovascular; ED = emergency department; ESRD = end stage renal disease; HD = hemodialysis; LIDI = long interdialytic interval.

References in the slide notes.

DIALIZE
Study design

Phase IIIb, randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of SZC for the treatment of hyperkalemia in ESRD patients on stable HD



[a]Predialysis central laboratory serum K^+ ≥5.5 mmol/L after the LIDI and ≥5.1 mmol/L after at least one short interdialytic interval; [b]During the first 4 weeks of the treatment period, the SZC and placebo doses were adjusted if the predialysis i-STAT® K^+ after the LIDI was >5.0 mmol/L (one weekly dose adjustment). If the predialysis i-STAT K^+ <4.0 mmol/L, dialysate K^+ concentration was increased by 0.5 or 1.0 mmol/L according to standard of care; if local practice did not include increasing dialysate K^+ concentrations or if the dialysate K^+ concentration could not be increased further, the SZC or placebo dose could be reduced by 5 g or held if already dosed at the minimum dose of 5 g. If during the initial 4 weeks, the dose of SZC or placebo was reduced or held and the predialysis i-STAT K^+ after the next LIDI was >5.0 mmol/L, every effort was made to increase the dose by 5 g or restart 5 g if it was held.

ESRD = end stage renal disease; HD = hemodialysis; LIDI = long interdialytic interval; R = randomization; SZC = sodium zirconium cyclosilicate; TIW = three times weekly.

Fishbane S et al. Article and supplemental data. *J Am Soc Nephrol*. 2019;30:1723-1733.

DIALIZE
Study endpoints

Primary Endpoint	**Percentage of patients maintaining serum K^+ of 4.0–5.0 mmol/L[a] during ≥3 of 4 HD treatments following the LIDI and who did not require rescue therapy[b] during the 4-week evaluation period (responders)**
Secondary Endpoints	
Efficacy	Proportion of patients requiring rescue therapy to reduce serum K^+ in the setting of severe hyperkalemia (serum K^+ >6 mmol/L)[b]
Safety	• Adverse events • Laboratory changes/vital signs, ECG changes • IDWG: difference between predialysis weight after LIDI and postdialysis weight from the previous dialysis session
Post Hoc Analysis	K^+ shift: difference between pre- and postdialysis K^+ K^+ gradient: difference between predialysis K^+ and the dialysate K^+ concentration

[a]Serum K^+ levels will be measured using i-STAT device and central laboratory. Dose adjustments will be made based on predialysis i-STAT K^+ levels; [b]Rescue therapy was any urgent therapeutic intervention considered necessary to reduce serum K^+ for severe hyperkalemia (serum K^+ >6.0 mmol/L). Use of rescue therapy included but was not limited to insulin/glucose, sodium bicarbonate, β-adrenergic agonists, potassium binders (SPS, CPS, patiromer), and any other form of renal replacement therapy including additional dialysis or reduction in dialysate K^+ concentration. Use of rescue therapy was not strictly protocolized and was left to the investigator's clinical judgement to be given in accordance with local practice patterns. No clinically justified therapy for severe acute hyperkalemia was withheld in study patients. Rescue therapy was followed by SZC dose adjustment, if appropriate, and documentation of the event.

CPS = calcium polystyrene sulfonate; ECG = electrocardiogram; HD = hemodialysis; IDWG = interdialytic weight gain; LIDI = long interdialytic interval; SPS = sodium polystyrene sulfonate; SZC = sodium zirconium cyclosilicate.

Fishbane S et al. Article and supplemental data. *J Am Soc Nephrol*. 2019;30:1723-1733.

DIALIZE
Primary efficacy endpoint – Proportion of responders

The proportion of responders[a] was significantly higher with SZC than placebo.
Sensitivity analysis results were consistent with the primary analysis.[b]



[a]Responders were defined as patients who, during the evaluation period, maintained a predialysis serum K^+ 4.0-5.0 mmol/L during ≥3 out of 4 HD treatments following the long interdialytic interval and who did not receive rescue therapy; [b]A sensitivity analysis was conducted to account for nonresponders with missing central laboratory assessment by using adjusted i-STAT K^+ data.

HD = hemodialysis; SZC = sodium zirconium cyclosilicate.

Fishbane S et al. Article and supplemental data. *J Am Soc Nephrol*. 2019;30:1723-1733.

LOKELMA REDUCED K+ LEVELS AND SUSTAINED K+ CONTROL IN HAEMODIALYSIS PATIENTS

Mean predialysis serum K⁺ levels over time in patients on haemodialysis*[1]



- 41% (n=40/97) of patients achieved 4.0-5.0 mmol/L (vs 1% for placebo [n = 1/99]) in at least three of four haemodialysis sessions following the long interdialytic interval, without need for rescue therapy.[2]

*DIALIZE, a Phase III, multicentre, placebo-controlled study in 196 patients with end-stage renal disease on stable dialysis for at least 3 months and persistent pre-dialysis hyperkalaemia.
Double-blind, randomised phase: LOKELMA 5 g or placebo once daily on non-dialysis days. The dose could be adjusted weekly in 5 g increments up to 15 g once daily. Primary endpoint: proportion of patients who maintained a pre-dialysis serum K⁺ between4.0 and 5.0 mmol/L on at least three out of four dialysis treatments after the long interdialytic interval and who did not receive rescue therapy during the evaluation period.[2]
†5 g once daily on non-dialysisdays (titrated in 5 g increments weekly to max 15 g once daily on non-dialysis days). The displayed error bars correspond to 95% confidence intervals.[1]
1. AstraZeneca AB. LOKELMA EU Summary of Product Characteristics 2020. 2. Fishbane S, Ford M, Fukagawa M, et al. J Am Soc Nephrol. 2019;30(9):1723-1733.

DIALIZE
Safety results

AE, n (%)[1]	SZC (n=96)	Placebo (n=99)
Patients with any AE	40 (41.7)	46 (46.5)
Patients with any SAE[a]	7 (7.3)	8 (8.1)
AEs leading to discontinuation	4 (4.2)[b]	2 (2.0)
Death	1 (1.0)[c]	0 (0.0)
AEs in >2% of patients		
Constipation	4 (4.2)	3 (3.0)
Diarrhea	4 (4.2)	6 (6.1)
Headache	3 (3.1)	2 (2.0)
Nasopharyngitis	3 (3.1)	5 (5.1)
Hyperkalemia	2 (2.1)	6 (6.1)
Hordeolum (stye)	2 (2.1)	0 (0.0)
Muscle spasms	2 (2.1)	2 (2.0)
Dizziness	1 (1.0)	4 (4.0)
Dyspnea	1 (1.0)	3 (3.0)
Pruritus	1 (1.0)	3 (3.0)
Shunt stenosis	1 (1.0)	3 (3.0)

- Most AEs reported were considered mild or moderate in intensity[1]
- Most common AE was **GI disorders**, with no difference between groups (19.8% with SZC vs. 17.2% with placebo)[1]
- Throughout the study, there were **no clinically meaningful changes in blood pressure or heart rate and there were no clinically significantly abnormal electrocardiogram results[1,2]**
- **All SAEs were considered not related to the study drug[1]**

[a]Including the event with death as an outcome and were considered not related to the study drug; [b]One event of hyperkalemia with SZC led to drug discontinuation and was considered unlikely related to the study drug; [c]SAE of peripheral arterial occlusive disease occurring 69 days after SZC start that led to death. The patient had a concomitant SAE of gangrene of the leg and feet starting 53 days after the first dose of SZC and 6 days after the last dose. It was judged by the investigators as not related to SZC.

AE = adverse event; GI = gastrointestinal; SAE = serious adverse event; SZC = sodium zirconium cyclosilicate.

1. Fishbane S et al. *J Am Soc Nephrol*. 2019;30:1723-1733; 2. In House Data, AstraZeneca Pharmaceuticals LP. CSR D9480C00006. April 26, 2019.

Practice Point 3.2.4:

Hyperkalemia associated with use of RASi can often be managed by measures to reduce the serum potassium levels rather than decreasing the dose or stopping RASi.

Strategies to control chronic hyperkalemia include dietary potassium restriction; discontinuation of potassium supplements, certain salt substitutes, and hyperkalemic drugs; adding potassium-wasting diuretics, and **oral potassium binders**

In CKD patients receiving RASi who develop hyperkalemia, the latter can be controlled with **newer oral potassium binders** in many patients, with the effect that RASi can be continued at the recommended dose

For the 1st time, a globally recognized Cardiology Guideline lists novel K^+ binders (sodium zirconium cyclosilicate, patiromer and sorbitex calcium) as options to manage hyperkalaemia

- Clearly defined hyperkalaemia
- RAASi uptitration and optimization when $K^+ < 5.0$ mmol/L
- Clear direction for action with novel K^+ binder >5.0 mmol/L



ESC European Society of Cardiology

European Heart Journal (2021) **00**, 1–128
doi:10.1093/eurheartj/ehab368

ESC GUIDELINES

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)

With the special contribution of the Heart Failure Association (HFA) of the ESC



Low K^+ Diet is not mentioned as option for the management of HK

Loop diuretics are mentioned only in the context of managing life-threatening HK, to help facilitate K^+ loss

SZC and patiromer are described as being ‘much better tolerated’ than SPS and CPS

SPS **should not** be used in the medium or long term as it may cause severe gastrointestinal side effects, including bowel necrosis

MAINTENANCE DOSING[1]

- **LOKELMA is a daily treatment option for hyperkalaemia (for non-dialysis patients)[1]**
- **Recommended dosing of LOKELMA to achieve and sustain normokalaemia[1]**

FOR ADULT (NON-DIALYSIS) PATIENTS

Correction phase

3×  **/day[a,b]**

10 g
for 24 to 48 hours

until normokalemia is achieved[a,b]

Maintenance phase

1×  **/day[a,b]**

5 g
for up to 1 year

To establish minimum effective dose, LOKELMA may be titrated
- Up to **10 g once daily** or
- Down to **5 g once every other day**

No more than **10 g once daily** should be used for maintenance therapy

New SmPC Update Based on DIALIZE Data

FOR HAEMODIALYSIS PATIENTS

RECOMMENDED STARTING DOSE

1×  **/non-dialysis days**

5 g

To establish normokalaemia, the dose may be titrated up or down weekly based on the predialysis serum K^+ after the long interdialytic interval

The dose could be adjusted at intervals of one week in increments of 5 g:
- **Up to 15 g once daily on non-dialysis days**

It is recommended to monitor serum K^+ weekly while the dose is adjusted. To maintain normokalaemia, it is recommended to monitor serum K^+ regularly (e.g., monthly or more frequently based on clinical judgement)

Serum K^+ levels should be monitored regularly during treatment. Monitoring frequency will depend upon a variety of factors, including other medications, progression of CKD and dietary K+ intake. If severe hypokalaemia should occur, LOKELMA should be discontinued and the patient is re-evaluated.
LOKELMA should be administered at least 2 hours before or 2 hours after oral medications with clinically meaningful gastric pH-dependent bioavailability. Refer to Summary of Product Characteristics for more information including examples of such medicines.

Serum K^+ levels should be monitored periodically during treatment
[a]If normokalaemia is not achieved within 48 hours of treatment, the same regimen can be continued for an additional 24 hours. If normokalaemia is not achieved after 72 hours of treatment, other treatment approaches should be considered; [b]Patients who miss a dose should be instructed to take the next usual dose at their normal time.[1]
1. AstraZeneca. LOKELMA Summary of Product Characteristics 2020.

Oral Administration

- **LOKELMA is a powder for oral suspension, available in 5 g or 10 g doses[1]**
- **Mix LOKELMA with 45 mL of water for oral administration[1]**

- ✓ Tasteless and odourless[1,2]
- ✓ May be taken with many other medications and with or without food[a1]
- ✓ No special conditions for storage[1]

Ensure patients stir well and drink suspension straight away while still cloudy (powder will not dissolve). Remind patients, if powder settles, to stir again before finishing drink[1]

Please see limited drug-drug Interactions for the types of drugs that cannot be co-administered with LOKELMA.
[a]LOKELMA should be administered at least 2 hours before or 2 hours after oral medications with clinically meaningful gastric pH-dependent bioavailability. LOKELMA can be taken without spacing of dosing times with oral medications that do not exhibit pH-dependent bioavailability.
1. AstraZeneca. LOKELMA Summary of Product Characteristics, 2020. 2. Stavros F, et al. *PLoS One*. 2014;9(12):e114686.

Safety and tolerability profile in clinical trials

- **5.7% of patients receiving LOKELMA reported edema-related events;[a] the events were more commonly seen in patients treated with 15 g. LOKELMA** 15-g dose is not approved for use in the EU
- No clinically significant changes in urinary sodium excretion, or serum magnesium and calcium levels, were observed with LOKELMA
- **4.1% of patients receiving LOKELMA developed hypokalemia (serum K^+ level <3.5 mEq/L), which resolved with dosage adjustment or discontinuation of LOKELMA**
- In a clinical drug–drug interaction study conducted in healthy individuals, co-administration of LOKELMA with amlodipine, clopidogrel, atorvastatin, furosemide, glipizide, warfarin, losartan, or levothyroxine did not result in clinically meaningful drug–drug interactions
- LOKELMA is not systemically absorbed or metabolized by the body
- LOKELMA can transiently increase gastric pH, therefore it should be administered at least 2 hours before or 2 hours after oral medications with clinically meaningful pH-dependent bioavailability[b] (anti-HIV, antifungal)
- LOKELMA can be co-administered without spacing of dosing times with oral medications that do not exhibit pH-dependent bioavailability

LOKELMA is not intended for use in place of emergency treatments; emergency treatment may require other temporary agents
[a]Includes generalized and peripheral edema
[b]**Azole antifungals (ketoconazole, itraconazole, and posaconazole); anti-HIV drugs (atazanavir, nelfinavir, indinavir, ritonavir, saquinavir, raltegravir, ledipasvir, and rilpivirine); tyrosine kinase inhibitors (erlotinib, dasatinib, and nilotinib)**
AstraZeneca AB. LOKELMA EU Summary of Product Characteristics 2020

LOKELMA summary of key characteristics

LOKELMA is indicated for the treatment of hyperkalemia in adults

	LOKELMA
MOA	Preferential K^+-binding in exchange for sodium and hydrogen[1]
Onset of action	As early as 1 hour after the first dose[2]
Efficacy data	Acute treatment and maintenance data up to 1 year[2]
Drug–drug interactions	Should be administered at least 2 hours before or 2 hour after oral medications with clinically meaningful gastric pH-dependent bioavailability[2*]
Location of K^+-binding	Throughout GI tract[2]
Tolerability	Associated with:[2] • Hypokalemia • Edema-related events

There is limited experience in patients with serum potassium concentrations greater than 6.5 mEq/L[2]
*Examples of medicines that should be administered before or after LOKELMA include azole antifungals (ketoconazole, itraconazole, and posaconazole); anti-HIV drugs (atazanavir, nelfinavir, indinavir, ritonavir, saquinavir, raltegravir, ledipasvir, and rilpivirine); tyrosine kinase inhibitors (erlotinib, dasatinib, and nilotinib)
GI, gastrointestinal; MOA, mechanism of action
1. Garimella PS, Jaber BL. *Am J Kidney Dis* 2016;67:545–547; 2. AstraZeneca AB. LOKELMA EU Summary of Product Characteristics 2020


ΖΗΣΕ
ΔΥΟ ΦΟΡΕΣ
ΑΧΕΠΑ